Bayer (BAYRY) is running an Australian study called “Treatment Patterns and Characteristics of Patients Receiving Androgen Receptor Pathway Inhibitors in a Real-world Setting in Australia: A ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer. This is an ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
In patients with prostate cancer, androgen receptor pathway inhibitors (ARPIs) extended the median time to no longer clinically benefitting (NLCB) to 11.1 months compared with the 6.9 months seen with ...
GlobalData on MSN
Acerand reports first-in-human trial results for ACE-106 therapy
ACE-106 demonstrated notable anti-tumour activity across different tumour types.
New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study in The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results